Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics develops briquilimab, a clinical-stage antibody therapy targeting KIT (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Company news centers on briquilimab clinical data from BEACON, open-label extension and ETESIAN studies, financial results and corporate updates, investor conference participation, financing activity and governance changes tied to its development strategy.
Jasper Therapeutics (Nasdaq:JSPR) reported second quarter 2026 results and detailed its post‑merger strategy following completion of the all‑stock acquisition of Kira Pharmaceuticals on July 16, 2026. Concurrently, Jasper closed a PIPE financing of non‑voting convertible preferred stock, generating approximately $132 million in gross proceeds, which the company believes will fund planned operations into the second half of 2028.
The combined company is advancing three key clinical assets: KP‑104, a Phase 2 basket trial in rare renal indications with interim data expected in Q4 2026; briquilimab, moving toward a pre‑BLA meeting with the FDA with next‑step guidance expected in Q1 2027; and KP‑701, for which a Phase 1 CTA/IND filing is targeted for Q1 2027. As of June 30, 2026, cash and cash equivalents were $7.3 million. Q2 2026 research and development expense was $5.1 million and general and administrative expense was $4.1 million, resulting in a net loss of $2.8 million, or $0.10 per basic and diluted share, compared with a net loss of $26.7 million, or $1.74 per share, in Q2 2025.
Jasper Therapeutics (Nasdaq: JSPR) has completed an all-stock acquisition of Kira Pharmaceuticals, creating a combined company focused on biologic therapies for immunologically-driven disorders. Concurrently, Jasper entered a private placement of non-voting convertible preferred stock expected to raise approximately $132 million, led by specialist life sciences investors, to fund the consolidated pipeline.
The portfolio centers on KP-104 for paroxysmal nocturnal hemoglobinuria and rare renal disorders, briquilimab for transplant and immunologic indications including SCID, and preclinical KP-701 for autoantibody-mediated diseases. Kira also out-licensed KP-301 and KP-402 to Mirador Therapeutics for a $12 million upfront payment plus potential milestones. According to Jasper Therapeutics, pro-forma cash, including the placement and out-licensing proceeds, is expected to fund operations and multiple clinical milestones through the second half of 2028, while the combined company continues to trade under the ticker JSPR.
Jasper Therapeutics (Nasdaq:JSPR) announced that its board has begun a comprehensive review of strategic alternatives to maximize shareholder value after assessing current market conditions.
Options include asset sales or licenses, collaborations, a company sale, business combination or merger, or an orderly wind-down, while continuing cost-saving efforts and regulatory compliance.
Jasper Therapeutics (Nasdaq:JSPR) reported first quarter 2026 results and a briquilimab clinical update. The company focuses on mast cell driven diseases such as chronic spontaneous urticaria (CSU) and asthma.
Jasper refiled a Phase 2b CSU protocol with the FDA, highlighted positive briquilimab data, held $14.1 million in cash and cash equivalents, and reported a net loss of $1.2 million for Q1 2026.
Jasper Therapeutics (Nasdaq: JSPR) reported Q4 and full-year 2025 results and clinical updates on briquilimab, an anti‑c‑Kit antibody for chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma. Key clinical signals: positive BEACON and open‑label extension CSU data, ETESIAN asthma proof‑of‑concept, dose selection for Phase 2b planned H2 2026. Financials: cash of $28.7M at Dec 31, 2025 and a 2025 net loss of $75.8M. Company noted Phase 2b enrollment timing is pending capital availability.
Jasper Therapeutics (Nasdaq: JSPR) announced management will present at the 46th Annual TD Cowen Healthcare Conference in Boston, March 2-4, 2026.
The company will participate in a Fireside Chat on Monday, March 2, 2026 at 3:50 PM ET. According to the company, a live webcast will be available on its investor website and an archived replay will remain online for 30 days.
Jasper Therapeutics (NASDAQ: JSPR) reported updated clinical data for briquilimab in chronic spontaneous urticaria (CSU) from the randomized BEACON Phase 1b/2a study and an open‑label extension. In the BEACON 240mg→180mg Q8W cohort (briquilimab, n=6) mean UAS7 fell by 31 points at 12 weeks; 83% had UAS7=0 by week 3 and 67% had UAS7=0 at week 12. In the open‑label extension, 58% of CSU patients (n=36) achieved UAS7=0 at 12 weeks and 75% reached UAS7≤6. Median follow‑up was 205 days in 63 patients. Safety findings were infrequent, predominantly low‑grade, and no dose‑limiting toxicities were observed. Jasper said data support dose selection for a Phase 2b CSU study planned for the second half of 2026.
Jasper Therapeutics (Nasdaq: JSPR) named Jeet Mahal as President and Chief Executive Officer and board member, effective Jan 5, 2026, with Thomas Wiggans appointed Executive Chairperson. Jasper is preparing to commence a registrational program for briquilimab in chronic spontaneous urticaria (CSU) and cited proof of concept in CSU, chronic inducible urticaria (CIndU) and asthma. The company will host an investor webinar on Jan 8, 2026 at 8:00 a.m. ET to present updated BEACON study and open-label extension data; slides and a webcast archive will be posted on investor relations.
Jasper Therapeutics (Nasdaq: JSPR) reported positive preliminary Phase 1b ETESIAN results for briquilimab in allergic asthma and closed an internal BEACON investigation. A single 180mg subcutaneous dose produced marked reductions in sputum eosinophils and serum tryptase and improved Early and Late Asthmatic Response (LAR %Max FEV1 +10.4% at 6 weeks, +8.7% at 12 weeks versus baseline). Briquilimab was well tolerated. The BEACON probe found no drug product issues; Jasper concluded the anomalous lack of CSU efficacy in 10 US patients likely reflected patient selection (9 of 10 likely not mast cell-driven). Jasper expects additional BEACON data in Q1 2026 and plans Phase 2b CSU dosing selection mid-2026.
Jasper Therapeutics (NASDAQ:JSPR) will host an investor webinar on Tuesday, December 2, 2025 at 8:00 am ET to present preliminary ETESIAN asthma data and findings from its investigation into anomalous BEACON CSU results reported in July. The session will include remarks from Jasper management and Dr. Martin Metz, M.D., lead EU investigator in BEACON, followed by a live Q&A. Registration is required and presentation slides plus live and archived webcast links will be posted on Jasper's Investor Relations Events page.